Rare penetrant mutations confer severe risk of common diseases

Petko Fiziev(Illumina (United States)), Jeremy F. McRae(Illumina (United States)), Jacob C. Ulirsch(Illumina (United States)), Jacqueline S. Dron(Broad Institute), Tobias Hamp(Illumina (United States)), Yanshen Yang(Illumina (United States)), Pierrick Wainschtein(The University of Queensland), Zijian Ni(University of Wisconsin–Madison), Joshua G. Schraiber(Illumina (United States)), Hong Gao(Illumina (United States)), Dylan Cable(Massachusetts Institute of Technology), Yair Field(Illumina (United States)), François Aguet(Illumina (United States)), Marc Fasnacht(Illumina (United States)), Ahmed A. Metwally(Illumina (United States)), Jeffrey Rogers(University of Wisconsin–Madison), Tomàs Marquès‐Bonet(Institució Catalana de Recerca i Estudis Avançats), Heidi L. Rehm(Broad Institute), Anne O’Donnell‐Luria(Broad Institute), Amit V. Khera(Broad Institute), Kyle Kai‐How Farh(Illumina (United States))
Science
June 1, 2023
Cited by 74

Abstract

We examined 454,712 exomes for genes associated with a wide spectrum of complex traits and common diseases and observed that rare, penetrant mutations in genes implicated by genome-wide association studies confer ~10-fold larger effects than common variants in the same genes. Consequently, an individual at the phenotypic extreme and at the greatest risk for severe, early-onset disease is better identified by a few rare penetrant variants than by the collective action of many common variants with weak effects. By combining rare variants across phenotype-associated genes into a unified genetic risk model, we demonstrate superior portability across diverse global populations compared with common-variant polygenic risk scores, greatly improving the clinical utility of genetic-based risk prediction.


Related Papers